Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. (RPHM) Stock Competitors & Peer Comparison
See (RPHM) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RPHM | $18.20 | +952.02% | 60.8M | -1.08 | -$16.80 | N/A |
| VRTX | $387.77 | +0.00% | 101.5B | 28.20 | $14.04 | N/A |
| REGN | $556.55 | -0.00% | 58.5B | 14.15 | $39.68 | +0.32% |
| ALNY | $429.93 | +0.00% | 56.7B | -174.40 | -$2.48 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $637.56 | +0.00% | 39.6B | 32.89 | $19.66 | N/A |
| BNTX | $111.00 | +0.00% | 27.1B | -67.94 | -$1.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $25.69 | +0.02% | 20B | -26.60 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
RPHM vs VRTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, VRTX has a market cap of 101.5B. Regarding current trading prices, RPHM is priced at $18.20, while VRTX trades at $387.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas VRTX's P/E ratio is 28.20. In terms of profitability, RPHM's ROE is +0.33%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, RPHM is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check VRTX's competition here
RPHM vs REGN Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, REGN has a market cap of 58.5B. Regarding current trading prices, RPHM is priced at $18.20, while REGN trades at $556.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas REGN's P/E ratio is 14.15. In terms of profitability, RPHM's ROE is +0.33%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RPHM is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check REGN's competition here
RPHM vs ALNY Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ALNY has a market cap of 56.7B. Regarding current trading prices, RPHM is priced at $18.20, while ALNY trades at $429.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ALNY's P/E ratio is -174.40. In terms of profitability, RPHM's ROE is +0.33%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, RPHM is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ALNY's competition here
RPHM vs SGEN Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RPHM is priced at $18.20, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RPHM's ROE is +0.33%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RPHM is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check SGEN's competition here
RPHM vs ARGX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ARGX has a market cap of 39.6B. Regarding current trading prices, RPHM is priced at $18.20, while ARGX trades at $637.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ARGX's P/E ratio is 32.89. In terms of profitability, RPHM's ROE is +0.33%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, RPHM is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ARGX's competition here
RPHM vs BNTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, BNTX has a market cap of 27.1B. Regarding current trading prices, RPHM is priced at $18.20, while BNTX trades at $111.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas BNTX's P/E ratio is -67.94. In terms of profitability, RPHM's ROE is +0.33%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, RPHM is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check BNTX's competition here
RPHM vs BGNE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RPHM is priced at $18.20, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RPHM's ROE is +0.33%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, RPHM is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check BGNE's competition here
RPHM vs SMMT Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, SMMT has a market cap of 20B. Regarding current trading prices, RPHM is priced at $18.20, while SMMT trades at $25.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas SMMT's P/E ratio is -26.60. In terms of profitability, RPHM's ROE is +0.33%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, RPHM is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check SMMT's competition here
RPHM vs DNA-WT Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RPHM is priced at $18.20, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RPHM's ROE is +0.33%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, RPHM is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check DNA-WT's competition here
RPHM vs INCY Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, INCY has a market cap of 16.8B. Regarding current trading prices, RPHM is priced at $18.20, while INCY trades at $81.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas INCY's P/E ratio is 20.30. In terms of profitability, RPHM's ROE is +0.33%, compared to INCY's ROE of +0.34%. Regarding short-term risk, RPHM is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check INCY's competition here
RPHM vs RPRX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RPRX has a market cap of 15.4B. Regarding current trading prices, RPHM is priced at $18.20, while RPRX trades at $35.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RPRX's P/E ratio is 15.92. In terms of profitability, RPHM's ROE is +0.33%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, RPHM is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RPRX's competition here
RPHM vs UTHR Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, UTHR has a market cap of 14B. Regarding current trading prices, RPHM is priced at $18.20, while UTHR trades at $301.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas UTHR's P/E ratio is 12.08. In terms of profitability, RPHM's ROE is +0.33%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RPHM is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check UTHR's competition here
RPHM vs GMAB Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, GMAB has a market cap of 13.9B. Regarding current trading prices, RPHM is priced at $18.20, while GMAB trades at $21.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas GMAB's P/E ratio is 11.75. In terms of profitability, RPHM's ROE is +0.33%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, RPHM is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check GMAB's competition here
RPHM vs KRTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RPHM is priced at $18.20, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RPHM's ROE is +0.33%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RPHM is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check KRTX's competition here
RPHM vs ASND Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ASND has a market cap of 11.6B. Regarding current trading prices, RPHM is priced at $18.20, while ASND trades at $195.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ASND's P/E ratio is -36.12. In terms of profitability, RPHM's ROE is +0.33%, compared to ASND's ROE of +1.91%. Regarding short-term risk, RPHM is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ASND's competition here
RPHM vs BMRN Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, RPHM is priced at $18.20, while BMRN trades at $56.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas BMRN's P/E ratio is 17.20. In terms of profitability, RPHM's ROE is +0.33%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, RPHM is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check BMRN's competition here
RPHM vs MRNA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MRNA has a market cap of 10.5B. Regarding current trading prices, RPHM is priced at $18.20, while MRNA trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MRNA's P/E ratio is -3.58. In terms of profitability, RPHM's ROE is +0.33%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, RPHM is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MRNA's competition here
RPHM vs EXEL Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, EXEL has a market cap of 10.4B. Regarding current trading prices, RPHM is priced at $18.20, while EXEL trades at $37.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas EXEL's P/E ratio is 18.50. In terms of profitability, RPHM's ROE is +0.33%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, RPHM is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check EXEL's competition here
RPHM vs BBIO Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, BBIO has a market cap of 9.6B. Regarding current trading prices, RPHM is priced at $18.20, while BBIO trades at $49.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas BBIO's P/E ratio is -12.20. In terms of profitability, RPHM's ROE is +0.33%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, RPHM is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check BBIO's competition here
RPHM vs RXDX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RPHM is priced at $18.20, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RPHM's ROE is +0.33%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RPHM is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RXDX's competition here
RPHM vs VRNA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, RPHM is priced at $18.20, while VRNA trades at $105.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas VRNA's P/E ratio is -101.15. In terms of profitability, RPHM's ROE is +0.33%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, RPHM is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check VRNA's competition here
RPHM vs IMGN Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RPHM is priced at $18.20, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RPHM's ROE is +0.33%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, RPHM is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check IMGN's competition here
RPHM vs TECH Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, RPHM is priced at $18.20, while TECH trades at $52.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas TECH's P/E ratio is 118.93. In terms of profitability, RPHM's ROE is +0.33%, compared to TECH's ROE of +0.06%. Regarding short-term risk, RPHM is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check TECH's competition here
RPHM vs BPMC Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RPHM is priced at $18.20, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RPHM's ROE is +0.33%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, RPHM is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check BPMC's competition here
RPHM vs MDGL Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MDGL has a market cap of 8.3B. Regarding current trading prices, RPHM is priced at $18.20, while MDGL trades at $359.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MDGL's P/E ratio is -29.52. In terms of profitability, RPHM's ROE is +0.33%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, RPHM is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MDGL's competition here
RPHM vs CERE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RPHM is priced at $18.20, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CERE's P/E ratio is -16.47. In terms of profitability, RPHM's ROE is +0.33%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RPHM is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CERE's competition here
RPHM vs ROIV Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ROIV has a market cap of 8.2B. Regarding current trading prices, RPHM is priced at $18.20, while ROIV trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ROIV's P/E ratio is -10.97. In terms of profitability, RPHM's ROE is +0.33%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, RPHM is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ROIV's competition here
RPHM vs ROIVW Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, RPHM is priced at $18.20, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, RPHM's ROE is +0.33%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, RPHM is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ROIVW's competition here
RPHM vs CORT Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CORT has a market cap of 7.7B. Regarding current trading prices, RPHM is priced at $18.20, while CORT trades at $73.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CORT's P/E ratio is 65.00. In terms of profitability, RPHM's ROE is +0.33%, compared to CORT's ROE of +0.20%. Regarding short-term risk, RPHM is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CORT's competition here
RPHM vs HALO Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, RPHM is priced at $18.20, while HALO trades at $64.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas HALO's P/E ratio is 14.90. In terms of profitability, RPHM's ROE is +0.33%, compared to HALO's ROE of +1.37%. Regarding short-term risk, RPHM is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check HALO's competition here
RPHM vs JAZZ Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, RPHM is priced at $18.20, while JAZZ trades at $113.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas JAZZ's P/E ratio is -16.79. In terms of profitability, RPHM's ROE is +0.33%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, RPHM is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check JAZZ's competition here
RPHM vs IONS Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, RPHM is priced at $18.20, while IONS trades at $41.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas IONS's P/E ratio is -24.49. In terms of profitability, RPHM's ROE is +0.33%, compared to IONS's ROE of -0.45%. Regarding short-term risk, RPHM is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check IONS's competition here
RPHM vs RVMD Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RVMD has a market cap of 6.7B. Regarding current trading prices, RPHM is priced at $18.20, while RVMD trades at $35.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RVMD's P/E ratio is -7.98. In terms of profitability, RPHM's ROE is +0.33%, compared to RVMD's ROE of -0.39%. Regarding short-term risk, RPHM is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RVMD's competition here
RPHM vs RETA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RPHM is priced at $18.20, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RETA's P/E ratio is -66.29. In terms of profitability, RPHM's ROE is +0.33%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RPHM is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RETA's competition here
RPHM vs RYTM Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, RPHM is priced at $18.20, while RYTM trades at $96.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RYTM's P/E ratio is -32.51. In terms of profitability, RPHM's ROE is +0.33%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, RPHM is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RYTM's competition here
RPHM vs RNA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RNA has a market cap of 5.9B. Regarding current trading prices, RPHM is priced at $18.20, while RNA trades at $46.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RNA's P/E ratio is -12.97. In terms of profitability, RPHM's ROE is +0.33%, compared to RNA's ROE of -0.33%. Regarding short-term risk, RPHM is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RNA's competition here
RPHM vs NUVL Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, RPHM is priced at $18.20, while NUVL trades at $76.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas NUVL's P/E ratio is -15.90. In terms of profitability, RPHM's ROE is +0.33%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, RPHM is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check NUVL's competition here
RPHM vs ABCM Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RPHM is priced at $18.20, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RPHM's ROE is +0.33%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RPHM is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ABCM's competition here
RPHM vs ISEE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RPHM is priced at $18.20, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RPHM's ROE is +0.33%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RPHM is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ISEE's competition here
RPHM vs AXSM Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, AXSM has a market cap of 5.5B. Regarding current trading prices, RPHM is priced at $18.20, while AXSM trades at $105.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas AXSM's P/E ratio is -21.62. In terms of profitability, RPHM's ROE is +0.33%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, RPHM is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check AXSM's competition here
RPHM vs ABVX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, RPHM is priced at $18.20, while ABVX trades at $71.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ABVX's P/E ratio is -20.31. In terms of profitability, RPHM's ROE is +0.33%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, RPHM is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ABVX's competition here
RPHM vs CRSP Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, RPHM is priced at $18.20, while CRSP trades at $56.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CRSP's P/E ratio is -10.61. In terms of profitability, RPHM's ROE is +0.33%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, RPHM is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CRSP's competition here
RPHM vs MRUS Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MRUS has a market cap of 5.1B. Regarding current trading prices, RPHM is priced at $18.20, while MRUS trades at $63.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MRUS's P/E ratio is -12.02. In terms of profitability, RPHM's ROE is +0.33%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, RPHM is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MRUS's competition here
RPHM vs ALKS Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ALKS has a market cap of 4.7B. Regarding current trading prices, RPHM is priced at $18.20, while ALKS trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ALKS's P/E ratio is 13.83. In terms of profitability, RPHM's ROE is +0.33%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, RPHM is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ALKS's competition here
RPHM vs VKTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, VKTX has a market cap of 4.6B. Regarding current trading prices, RPHM is priced at $18.20, while VKTX trades at $39.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas VKTX's P/E ratio is -26.80. In terms of profitability, RPHM's ROE is +0.33%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, RPHM is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check VKTX's competition here
RPHM vs ALPN Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RPHM is priced at $18.20, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RPHM's ROE is +0.33%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RPHM is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ALPN's competition here
RPHM vs TGTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, TGTX has a market cap of 4.4B. Regarding current trading prices, RPHM is priced at $18.20, while TGTX trades at $27.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas TGTX's P/E ratio is 73.34. In terms of profitability, RPHM's ROE is +0.33%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, RPHM is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check TGTX's competition here
RPHM vs CYTK Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, RPHM is priced at $18.20, while CYTK trades at $34.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CYTK's P/E ratio is -7.21. In terms of profitability, RPHM's ROE is +0.33%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, RPHM is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CYTK's competition here
RPHM vs KRYS Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, RPHM is priced at $18.20, while KRYS trades at $143.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas KRYS's P/E ratio is 30.35. In terms of profitability, RPHM's ROE is +0.33%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, RPHM is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check KRYS's competition here
RPHM vs SLNO Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, SLNO has a market cap of 4.3B. Regarding current trading prices, RPHM is priced at $18.20, while SLNO trades at $83.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas SLNO's P/E ratio is -19.23. In terms of profitability, RPHM's ROE is +0.33%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, RPHM is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check SLNO's competition here
RPHM vs ACAD Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, RPHM is priced at $18.20, while ACAD trades at $25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ACAD's P/E ratio is 18.89. In terms of profitability, RPHM's ROE is +0.33%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, RPHM is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ACAD's competition here
RPHM vs OPT Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RPHM is priced at $18.20, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas OPT's P/E ratio is -1.52. In terms of profitability, RPHM's ROE is +0.33%, compared to OPT's ROE of +2.60%. Regarding short-term risk, RPHM is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check OPT's competition here
RPHM vs MRTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RPHM is priced at $18.20, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RPHM's ROE is +0.33%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RPHM is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MRTX's competition here
RPHM vs ADMA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, RPHM is priced at $18.20, while ADMA trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ADMA's P/E ratio is 20.24. In terms of profitability, RPHM's ROE is +0.33%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, RPHM is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ADMA's competition here
RPHM vs PCVX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, PCVX has a market cap of 4.1B. Regarding current trading prices, RPHM is priced at $18.20, while PCVX trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas PCVX's P/E ratio is -7.65. In terms of profitability, RPHM's ROE is +0.33%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, RPHM is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check PCVX's competition here
RPHM vs ACLX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, RPHM is priced at $18.20, while ACLX trades at $72.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ACLX's P/E ratio is -20.83. In terms of profitability, RPHM's ROE is +0.33%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, RPHM is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ACLX's competition here
RPHM vs ZLAB Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, RPHM is priced at $18.20, while ZLAB trades at $34.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ZLAB's P/E ratio is -17.82. In terms of profitability, RPHM's ROE is +0.33%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, RPHM is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ZLAB's competition here
RPHM vs AKRO Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, RPHM is priced at $18.20, while AKRO trades at $48.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas AKRO's P/E ratio is -12.68. In terms of profitability, RPHM's ROE is +0.33%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, RPHM is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check AKRO's competition here
RPHM vs PTCT Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, PTCT has a market cap of 3.8B. Regarding current trading prices, RPHM is priced at $18.20, while PTCT trades at $45.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas PTCT's P/E ratio is 6.83. In terms of profitability, RPHM's ROE is +0.33%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, RPHM is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check PTCT's competition here
RPHM vs AAPG Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, AAPG has a market cap of 3.8B. Regarding current trading prices, RPHM is priced at $18.20, while AAPG trades at $40.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas AAPG's P/E ratio is -54.87. In terms of profitability, RPHM's ROE is +0.33%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, RPHM is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check AAPG's competition here
RPHM vs TLX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, RPHM is priced at $18.20, while TLX trades at $10.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas TLX's P/E ratio is 124.22. In terms of profitability, RPHM's ROE is +0.33%, compared to TLX's ROE of +0.10%. Regarding short-term risk, RPHM is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check TLX's competition here
RPHM vs RYZB Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RPHM is priced at $18.20, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RPHM's ROE is +0.33%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RPHM is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RYZB's competition here
RPHM vs CBAY Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RPHM is priced at $18.20, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RPHM's ROE is +0.33%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RPHM is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CBAY's competition here
RPHM vs SWTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RPHM is priced at $18.20, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RPHM's ROE is +0.33%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, RPHM is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check SWTX's competition here
RPHM vs MLTX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, RPHM is priced at $18.20, while MLTX trades at $54.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MLTX's P/E ratio is -19.95. In terms of profitability, RPHM's ROE is +0.33%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, RPHM is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MLTX's competition here
RPHM vs PTGX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, RPHM is priced at $18.20, while PTGX trades at $54.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas PTGX's P/E ratio is 77.70. In terms of profitability, RPHM's ROE is +0.33%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, RPHM is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check PTGX's competition here
RPHM vs LEGN Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, RPHM is priced at $18.20, while LEGN trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas LEGN's P/E ratio is -20.75. In terms of profitability, RPHM's ROE is +0.33%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, RPHM is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check LEGN's competition here
RPHM vs APLS Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, APLS has a market cap of 3.4B. Regarding current trading prices, RPHM is priced at $18.20, while APLS trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas APLS's P/E ratio is -14.52. In terms of profitability, RPHM's ROE is +0.33%, compared to APLS's ROE of -1.16%. Regarding short-term risk, RPHM is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check APLS's competition here
RPHM vs MIRM Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MIRM has a market cap of 3.3B. Regarding current trading prices, RPHM is priced at $18.20, while MIRM trades at $64.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MIRM's P/E ratio is -53.83. In terms of profitability, RPHM's ROE is +0.33%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, RPHM is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MIRM's competition here
RPHM vs MTSR Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MTSR has a market cap of 3.2B. Regarding current trading prices, RPHM is priced at $18.20, while MTSR trades at $30.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MTSR's P/E ratio is -10.50. In terms of profitability, RPHM's ROE is +0.33%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, RPHM is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MTSR's competition here
RPHM vs SRRK Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, SRRK has a market cap of 3.1B. Regarding current trading prices, RPHM is priced at $18.20, while SRRK trades at $32.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas SRRK's P/E ratio is -10.95. In terms of profitability, RPHM's ROE is +0.33%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, RPHM is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check SRRK's competition here
RPHM vs LGND Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, RPHM is priced at $18.20, while LGND trades at $152.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas LGND's P/E ratio is -38.52. In terms of profitability, RPHM's ROE is +0.33%, compared to LGND's ROE of -0.09%. Regarding short-term risk, RPHM is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check LGND's competition here
RPHM vs KYMR Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, RPHM is priced at $18.20, while KYMR trades at $39.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas KYMR's P/E ratio is -11.67. In terms of profitability, RPHM's ROE is +0.33%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, RPHM is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check KYMR's competition here
RPHM vs XENE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, RPHM is priced at $18.20, while XENE trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas XENE's P/E ratio is -10.61. In terms of profitability, RPHM's ROE is +0.33%, compared to XENE's ROE of -0.32%. Regarding short-term risk, RPHM is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check XENE's competition here
RPHM vs NAMS Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, NAMS has a market cap of 2.9B. Regarding current trading prices, RPHM is priced at $18.20, while NAMS trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas NAMS's P/E ratio is -16.18. In terms of profitability, RPHM's ROE is +0.33%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, RPHM is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check NAMS's competition here
RPHM vs MORF Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, RPHM is priced at $18.20, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MORF's P/E ratio is -14.88. In terms of profitability, RPHM's ROE is +0.33%, compared to MORF's ROE of -0.16%. Regarding short-term risk, RPHM is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MORF's competition here
RPHM vs MOR Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, RPHM is priced at $18.20, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MOR's P/E ratio is -12.64. In terms of profitability, RPHM's ROE is +0.33%, compared to MOR's ROE of -1.84%. Regarding short-term risk, RPHM is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MOR's competition here
RPHM vs CRNX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, RPHM is priced at $18.20, while CRNX trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CRNX's P/E ratio is -7.34. In terms of profitability, RPHM's ROE is +0.33%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, RPHM is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CRNX's competition here
RPHM vs RARE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RARE has a market cap of 2.8B. Regarding current trading prices, RPHM is priced at $18.20, while RARE trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RARE's P/E ratio is -5.29. In terms of profitability, RPHM's ROE is +0.33%, compared to RARE's ROE of -2.37%. Regarding short-term risk, RPHM is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RARE's competition here
RPHM vs ARWR Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, ARWR has a market cap of 2.8B. Regarding current trading prices, RPHM is priced at $18.20, while ARWR trades at $17.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas ARWR's P/E ratio is -16.66. In terms of profitability, RPHM's ROE is +0.33%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, RPHM is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check ARWR's competition here
RPHM vs IMVT Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, RPHM is priced at $18.20, while IMVT trades at $15.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas IMVT's P/E ratio is -5.60. In terms of profitability, RPHM's ROE is +0.33%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, RPHM is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check IMVT's competition here
RPHM vs KDNY Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, RPHM is priced at $18.20, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas KDNY's P/E ratio is -12.47. In terms of profitability, RPHM's ROE is +0.33%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, RPHM is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check KDNY's competition here
RPHM vs IBRX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, IBRX has a market cap of 2.7B. Regarding current trading prices, RPHM is priced at $18.20, while IBRX trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas IBRX's P/E ratio is -5.87. In terms of profitability, RPHM's ROE is +0.33%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, RPHM is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check IBRX's competition here
RPHM vs MYOV Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, RPHM is priced at $18.20, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas MYOV's P/E ratio is -14.05. In terms of profitability, RPHM's ROE is +0.33%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, RPHM is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check MYOV's competition here
RPHM vs KNSA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, RPHM is priced at $18.20, while KNSA trades at $32.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas KNSA's P/E ratio is 673.00. In terms of profitability, RPHM's ROE is +0.33%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, RPHM is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check KNSA's competition here
RPHM vs CPRX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, RPHM is priced at $18.20, while CPRX trades at $20.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CPRX's P/E ratio is 12.24. In terms of profitability, RPHM's ROE is +0.33%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, RPHM is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CPRX's competition here
RPHM vs RXRX Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, RXRX has a market cap of 2.4B. Regarding current trading prices, RPHM is priced at $18.20, while RXRX trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas RXRX's P/E ratio is -3.15. In terms of profitability, RPHM's ROE is +0.33%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, RPHM is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check RXRX's competition here
RPHM vs VCYT Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, VCYT has a market cap of 2.4B. Regarding current trading prices, RPHM is priced at $18.20, while VCYT trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas VCYT's P/E ratio is 90.32. In terms of profitability, RPHM's ROE is +0.33%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, RPHM is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check VCYT's competition here
RPHM vs PRVB Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, RPHM is priced at $18.20, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas PRVB's P/E ratio is -16.43. In terms of profitability, RPHM's ROE is +0.33%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, RPHM is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check PRVB's competition here
RPHM vs LBPH Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, RPHM is priced at $18.20, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas LBPH's P/E ratio is -26.66. In terms of profitability, RPHM's ROE is +0.33%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, RPHM is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check LBPH's competition here
RPHM vs BLTE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, BLTE has a market cap of 2.3B. Regarding current trading prices, RPHM is priced at $18.20, while BLTE trades at $72.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas BLTE's P/E ratio is -46.17. In terms of profitability, RPHM's ROE is +0.33%, compared to BLTE's ROE of -0.37%. Regarding short-term risk, RPHM is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check BLTE's competition here
RPHM vs CNTA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, RPHM is priced at $18.20, while CNTA trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas CNTA's P/E ratio is -9.12. In terms of profitability, RPHM's ROE is +0.33%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, RPHM is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check CNTA's competition here
RPHM vs DICE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, RPHM is priced at $18.20, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas DICE's P/E ratio is -21.91. In terms of profitability, RPHM's ROE is +0.33%, compared to DICE's ROE of +0.56%. Regarding short-term risk, RPHM is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check DICE's competition here
RPHM vs APGE Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, RPHM is priced at $18.20, while APGE trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas APGE's P/E ratio is -9.02. In terms of profitability, RPHM's ROE is +0.33%, compared to APGE's ROE of -0.23%. Regarding short-term risk, RPHM is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check APGE's competition here
RPHM vs TARS Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, TARS has a market cap of 2.2B. Regarding current trading prices, RPHM is priced at $18.20, while TARS trades at $51.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas TARS's P/E ratio is -23.02. In terms of profitability, RPHM's ROE is +0.33%, compared to TARS's ROE of -0.32%. Regarding short-term risk, RPHM is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check TARS's competition here
RPHM vs FOLD Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, FOLD has a market cap of 2.2B. Regarding current trading prices, RPHM is priced at $18.20, while FOLD trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas FOLD's P/E ratio is -59.92. In terms of profitability, RPHM's ROE is +0.33%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, RPHM is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check FOLD's competition here
RPHM vs OCUL Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, OCUL has a market cap of 2.2B. Regarding current trading prices, RPHM is priced at $18.20, while OCUL trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas OCUL's P/E ratio is -9.92. In terms of profitability, RPHM's ROE is +0.33%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, RPHM is more volatile compared to OCUL. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check OCUL's competition here
RPHM vs DNLI Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, DNLI has a market cap of 2.2B. Regarding current trading prices, RPHM is priced at $18.20, while DNLI trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas DNLI's P/E ratio is -5.27. In terms of profitability, RPHM's ROE is +0.33%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, RPHM is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check DNLI's competition here
RPHM vs LQDA Comparison August 2025
RPHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPHM stands at 60.8M. In comparison, LQDA has a market cap of 2.2B. Regarding current trading prices, RPHM is priced at $18.20, while LQDA trades at $24.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPHM currently has a P/E ratio of -1.08, whereas LQDA's P/E ratio is -14.74. In terms of profitability, RPHM's ROE is +0.33%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, RPHM is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for RPHM.Check LQDA's competition here